- Home
- SD vs ASMB Comparison
SD vs ASMB Comparison
Compare SD & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SD | ASMB |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.8M | 512.1M |
| IPO Year | 2006 | 2010 |
Fundamental Metrics
Financial Performance| Metric | SD | ASMB |
|---|---|---|
| Price | $13.92 | $25.11 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $15.00 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 246.0K | 142.0K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | 12.43 | ★ 91.78 |
| EPS | ★ 0.50 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.65 | N/A |
| Revenue Next Year | $1.75 | $638.39 |
| P/E Ratio | $27.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $17.98 |
| 52 Week High | $18.45 | $39.71 |
Technical Indicators
Market Signals| Indicator | SD | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 46.05 |
| Support Level | $13.26 | $21.80 |
| Resistance Level | $13.99 | $30.36 |
| Average True Range (ATR) | 0.29 | 1.31 |
| MACD | 0.03 | -0.13 |
| Stochastic Oscillator | 42.62 | 24.93 |
Price Performance
Historical ComparisonAbout SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. The company's primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.